| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Payments of contingent consideration | - | - | - | 0 |
| Net cash used in financing activities | -45,551 | -43,382 | -38,779 | -529,306 |
| Effect of exchange rate changes on cash | -3,740 | -4,479 | -1,416 | 2,326 |
| Net increase (decrease) in cash and cash equivalents | 307,266 | 270,974 | 105,961 | -79,679 |
| Cash and cash equivalents at beginning of period | 942,842 | - | - | - |
| Cash and cash equivalents at end of period | 1,250,108 | - | - | - |
BIOMARIN PHARMACEUTICAL INC (BMRN)
BIOMARIN PHARMACEUTICAL INC (BMRN)